FRANKFURT – CureVac has recently shared encouraging outcomes from its latest COVID-19 vaccine trials, conducted in partnership with GSK. The preliminary data indicates that the vaccines, including a monovalent and a bivalent candidate, have generated strong immune responses even with lower dosages and are well-tolerated.
The monovalent vaccine candidate is designed to target the spike protein of the Omicron BA.4-5 variant, whereas the bivalent vaccine candidate aims at the spike proteins of both the Omicron BA.4-5 variant and the original SARS-CoV-2 virus. These results mark a significant step forward in the ongoing efforts to develop effective vaccines against emerging variants of COVID-19.
As the company announces these positive trial results, it is also preparing for discussions about advancing to a Phase 3 trial. This next phase is crucial for further evaluating the efficacy and safety of the vaccine candidates on a larger scale. The progression to Phase 3 will bring the vaccines one step closer to potential approval and public availability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
